![Yüksel Ürün(@DrYukselUrun) 's Twitter Profileg](https://pbs.twimg.com/profile_images/1731270076806889472/ffCiPa-W_200x200.jpg)
Yüksel Ürün
@DrYukselUrun
Prof. Medical Oncologist 🔬 @AnkaraUni 🎓 Advocate for #Diversity & #Equity 🌟 Genitourinary Cancer
ID:2798480350
https://yukselurun.com/ 01-10-2014 17:42:21
10,8K Tweet
6,6K Takipçi
582 Takip Edilen
![Heinrich Weber(@GlobalHeinrich) 's Twitter Profile Photo Heinrich Weber(@GlobalHeinrich) 's Twitter Profile Photo](https://pbs.twimg.com/profile_images/1785695160464031744/hFWxshZm_200x200.jpg)
Yüksel Ürün ASCO Toni Choueiri, MD Nazli Dizman Emre Yekedüz Marc Machaalani Congratulations on the groundbreaking review on IO rechallenge in mRCC! Such insights are crucial for future treatment paradigms.
![Yüksel Ürün(@DrYukselUrun) 's Twitter Profile Photo Yüksel Ürün(@DrYukselUrun) 's Twitter Profile Photo](https://pbs.twimg.com/profile_images/1731270076806889472/ffCiPa-W_200x200.jpg)
![Yüksel Ürün(@DrYukselUrun) 's Twitter Profile Photo Yüksel Ürün(@DrYukselUrun) 's Twitter Profile Photo](https://pbs.twimg.com/profile_images/1731270076806889472/ffCiPa-W_200x200.jpg)
With the Premier League title on the line on the final day, all I see are posts about Jurgen Klopp!
RESPECT!
Premier League Liverpool FC #YNWA
![Yüksel Ürün (@DrYukselUrun) on Twitter photo 2024-05-19 12:51:53 With the Premier League title on the line on the final day, all I see are posts about Jurgen Klopp! RESPECT! @premierleague @LFC #YNWA With the Premier League title on the line on the final day, all I see are posts about Jurgen Klopp! RESPECT! @premierleague @LFC #YNWA](https://pbs.twimg.com/media/GN8Wf-FWQAAbPvZ.png)
![Yüksel Ürün(@DrYukselUrun) 's Twitter Profile Photo Yüksel Ürün(@DrYukselUrun) 's Twitter Profile Photo](https://pbs.twimg.com/profile_images/1731270076806889472/ffCiPa-W_200x200.jpg)
A timely and clinically relevant review!
This review provides crucial insights into the treatment of metastatic renal cell carcinoma (mRCC). Congratulations to the entire team on this important contribution! 👏👏👏 ASCO Toni Choueiri, MD Nazli Dizman Emre Yekedüz Marc Machaalani
![Deniz Can Guven(@DenizCanGuven1) 's Twitter Profile Photo Deniz Can Guven(@DenizCanGuven1) 's Twitter Profile Photo](https://pbs.twimg.com/profile_images/1233827983816785920/sIKpuig3_200x200.jpg)
Join us next Monday for a great YO4YO Clinical Case Discussion with the rising star of Ankara Üniversitesi and the young king of #OncTwitter for 🇹🇷🇹🇷 Erman Akkus
Learning from the great mentors Yüksel Ürün Emre Yekedüz and already taking the stage👏👏
Expect a very strong 🇹🇷🇹🇷 YOs
![Yüksel Ürün(@DrYukselUrun) 's Twitter Profile Photo Yüksel Ürün(@DrYukselUrun) 's Twitter Profile Photo](https://pbs.twimg.com/profile_images/1731270076806889472/ffCiPa-W_200x200.jpg)
![Erman Akkus(@Erman_Akkus) 's Twitter Profile Photo Erman Akkus(@Erman_Akkus) 's Twitter Profile Photo](https://pbs.twimg.com/profile_images/1451492444344922116/4k5Kxdfd_200x200.jpg)
📢🗓️Add to calendar! 🔆
YO4YO Virtual Clinical Case Discussion session ESMO - Eur. Oncology #YOC
✅'Approaching a genomic profiling report for choosing the next line of therapy' 🧬
We will present and discuss the cases on Monday 27, 18.00 CEST
Big thanks to ESMO - Eur. Oncology #YOC for organizing
![Erman Akkus (@Erman_Akkus) on Twitter photo 2024-05-19 10:09:42 📢🗓️Add to calendar! 🔆 YO4YO Virtual Clinical Case Discussion session @myESMO #YOC ✅'Approaching a genomic profiling report for choosing the next line of therapy' 🧬 We will present and discuss the cases on Monday 27, 18.00 CEST Big thanks to @myESMO #YOC for organizing 📢🗓️Add to calendar! 🔆 YO4YO Virtual Clinical Case Discussion session @myESMO #YOC ✅'Approaching a genomic profiling report for choosing the next line of therapy' 🧬 We will present and discuss the cases on Monday 27, 18.00 CEST Big thanks to @myESMO #YOC for organizing](https://pbs.twimg.com/media/GN7xoEUW0AAgAnD.jpg)
![Yüksel Ürün(@DrYukselUrun) 's Twitter Profile Photo Yüksel Ürün(@DrYukselUrun) 's Twitter Profile Photo](https://pbs.twimg.com/profile_images/1731270076806889472/ffCiPa-W_200x200.jpg)
Inspiring Resilience: Age is Just a Number!
We must look beyond age when evaluating patients. Their vitality and spirit are just as important as any medical assessment!
Enrique Soto Ravindran Kanesvaran OncoAlert American Geriatrics Society SIOG #age Ishwaria Subbiah, MD MS FASCO
![Christian Rolfo(@ChristianRolfo) 's Twitter Profile Photo Christian Rolfo(@ChristianRolfo) 's Twitter Profile Photo](https://pbs.twimg.com/profile_images/1431992952339972097/2KxAbOmc_200x200.jpg)
Very proud of the great Meeting on #CTC24 hosted in the magical city of Granada Spain 🇪🇸. M JOSE SERRANO (LB&Cancer Interception group) our International Society of Liquid Biopsy Vice president is organizing with Massimo Cristofanilli, MD, FACP our past-president. Great agenda and faculty! Don’t miss it!
![Yüksel Ürün(@DrYukselUrun) 's Twitter Profile Photo Yüksel Ürün(@DrYukselUrun) 's Twitter Profile Photo](https://pbs.twimg.com/profile_images/1731270076806889472/ffCiPa-W_200x200.jpg)
![Yüksel Ürün(@DrYukselUrun) 's Twitter Profile Photo Yüksel Ürün(@DrYukselUrun) 's Twitter Profile Photo](https://pbs.twimg.com/profile_images/1731270076806889472/ffCiPa-W_200x200.jpg)
![Yüksel Ürün(@DrYukselUrun) 's Twitter Profile Photo Yüksel Ürün(@DrYukselUrun) 's Twitter Profile Photo](https://pbs.twimg.com/profile_images/1731270076806889472/ffCiPa-W_200x200.jpg)
Cancer Statistics 2024: Deaths drop, incidences increase, prevention needed!
ACS Journal Cancer OncoAlert American Cancer Society Karen Knudsen, MBA PhD Union for International #CancerControl Oncology Brothers
doi.org/10.1002/cncr.3…
![Yüksel Ürün (@DrYukselUrun) on Twitter photo 2024-05-18 08:43:49 Cancer Statistics 2024: Deaths drop, incidences increase, prevention needed! @JournalCancer @OncoAlert @AmericanCancer @AmerCancerCEO @uicc @OncBrothers doi.org/10.1002/cncr.3… Cancer Statistics 2024: Deaths drop, incidences increase, prevention needed! @JournalCancer @OncoAlert @AmericanCancer @AmerCancerCEO @uicc @OncBrothers doi.org/10.1002/cncr.3…](https://pbs.twimg.com/media/GN2UWZrX0AAlmap.jpg)
![Yüksel Ürün(@DrYukselUrun) 's Twitter Profile Photo Yüksel Ürün(@DrYukselUrun) 's Twitter Profile Photo](https://pbs.twimg.com/profile_images/1731270076806889472/ffCiPa-W_200x200.jpg)
![Yüksel Ürün(@DrYukselUrun) 's Twitter Profile Photo Yüksel Ürün(@DrYukselUrun) 's Twitter Profile Photo](https://pbs.twimg.com/profile_images/1731270076806889472/ffCiPa-W_200x200.jpg)
Next-generation sequencing is key for managing NSCLC, enabling comprehensive molecular profiling for targeted therapies. Best practice recommendations for reporting ensure clear, actionable results. #LungCancer #NGS #Oncology #PrecisionMedicine
Umberto Malapelle Christian Rolfo
![Yüksel Ürün (@DrYukselUrun) on Twitter photo 2024-05-16 07:00:02 Next-generation sequencing is key for managing NSCLC, enabling comprehensive molecular profiling for targeted therapies. Best practice recommendations for reporting ensure clear, actionable results. #LungCancer #NGS #Oncology #PrecisionMedicine @UmbertoMalapel1 @ChristianRolfo Next-generation sequencing is key for managing NSCLC, enabling comprehensive molecular profiling for targeted therapies. Best practice recommendations for reporting ensure clear, actionable results. #LungCancer #NGS #Oncology #PrecisionMedicine @UmbertoMalapel1 @ChristianRolfo](https://pbs.twimg.com/media/GNrplmiXQAAT6kI.jpg)
![Yüksel Ürün(@DrYukselUrun) 's Twitter Profile Photo Yüksel Ürün(@DrYukselUrun) 's Twitter Profile Photo](https://pbs.twimg.com/profile_images/1731270076806889472/ffCiPa-W_200x200.jpg)
Perioperative nivolumab for resectable NSCLC improves 18-month event-free survival to 70.2% vs. 50.0% with chemo and achieves a 25.3% pathological complete response rate. #LungCancer #Immunotherapy #NSCLC NEJM OncoAlert
![Yüksel Ürün (@DrYukselUrun) on Twitter photo 2024-05-16 06:55:23 Perioperative nivolumab for resectable NSCLC improves 18-month event-free survival to 70.2% vs. 50.0% with chemo and achieves a 25.3% pathological complete response rate. #LungCancer #Immunotherapy #NSCLC @NEJM @OncoAlert Perioperative nivolumab for resectable NSCLC improves 18-month event-free survival to 70.2% vs. 50.0% with chemo and achieves a 25.3% pathological complete response rate. #LungCancer #Immunotherapy #NSCLC @NEJM @OncoAlert](https://pbs.twimg.com/media/GNrohV_XAAE1nwi.jpg)
![Yüksel Ürün(@DrYukselUrun) 's Twitter Profile Photo Yüksel Ürün(@DrYukselUrun) 's Twitter Profile Photo](https://pbs.twimg.com/profile_images/1731270076806889472/ffCiPa-W_200x200.jpg)